Osteo Arthritis of the Knee Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee
| Verified date | July 2012 |
| Source | Anchen Pharmaceuticals, Inc |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
The objective of this study is to evaluate the clinical equivalence and safety of the Test
formulation of diclofenac sodium topical gel 1% (Anchen Pharmaceuticals, Inc.) compared to
the marketed formulation Voltaren® Gel (diclofenac sodium topical gel) 1% (Novartis) in
patients with osteoarthritis of the knee.
The efficacy of both the Test and Reference formulations will also be compared to the
Placebo gel to determine Superiority.
| Status | Completed |
| Enrollment | 749 |
| Est. completion date | April 2012 |
| Est. primary completion date | April 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 35 Years and older |
| Eligibility |
Inclusion Criteria: 1. Ambulatory Male and Non Pregnant Females 35 years and older diagnosed with osteoarthritis (according to the American College of Rheumatology Criteria) in one or both knees. ACR Criteria includes, Knee Pain and at least 3 of the following: 1. age = 50 2. stiffness lasting < 30 mins 3. bony tenderness 4. crepitus 5. bony enlargement 6. no palpable warmth 2. Symptom onset of > 6 Months prior to Screening for the target knee. 3. If female and of child-bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom + spermicide, IUD, oral, transdermal, injected or implanted hormonal contraceptives). 4. Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc) requiring the use of oral or topical treatments (NSAIDS or acetaminophen) for > 15 days in the 30 days prior to Screening. 5. Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease based upon the Kellgren-Lawrence disease severity scale. 6. After a 7 day wash out of all pain medication has baseline pain on movement score of = 50mm on a 100-mm Visual Analogue Scale for the target knee. 7. After a 7 day wash out of all pain medication has baseline WOMAC pain sub scale of = 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee. 8. Willing and able to use only acetaminophen as rescue medication 9. Willing and able to comply with the study requirements. Exclusion Criteria: 1. Females who are pregnant, breast feeding, or planning a pregnancy 2. Radiograph of the target knee within the previous year with a Grade 4 score on the Kellgren-Lawrence disease severity scale. 24 3. History of osteoarthritis in the contralateral knee requiring medication (OTC or prescription) within 12 months of screening. 4. After a 7 day wash out of all pain medication has baseline pain on movement score of = 20mm on a 100-mm Visual Analogue Scale for the contralateral knee immediately prior to randomization. 5. Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty arthritis) or rheumatoid arthritis. 6. Known history of other chronic inflammatory diseases, (e.g.,colitis) or fibromyalgia. 7. History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease. 8. History of coronary artery bypass graft within 6 months of screening. 9. Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (max 162mg daily) taken for at least 3 months prior to enrollment and maintained throughout the duration of the study. 10. Use of warfarin or other anticoagulant therapy within 30 days of screening. 11. Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of screening or during the study. 12. Known history of gastrointestinal bleeding or peptic ulcer disease. 13. Abnormal screening clinical laboratory evaluations which the Investigator determines are clinically significant. 14. Known allergy to aspirin or NSAIDs. 15. Results from liver function tests that are more than two times the upper limit of the normal range at screening. 16. Any other acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the Patient at risk by participating in the study. 17. Concomitant use of corticosteroids (any formulation) or use within 30 days of study randomization. 18. Receipt of any drug as part of a research study within 30 days prior to screening. 19. Previous participation in this study. |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | Novum Investigator Site | Adventura | Florida |
| United States | Novum Investigator Site | Anaheim | California |
| United States | Novum Investigator Site | Beavercreek | Oklahoma |
| United States | Novum Investigator Site | Billings | Montana |
| United States | Novum Investigator Site | Birmingham | Alabama |
| United States | Novum Investigator Site | Bookville | Florida |
| United States | Novum Investigator Site | Bradenton | Florida |
| United States | Novum Investigator Site | Carmichael | California |
| United States | Novum Investigator Site | Cary | North Carolina |
| United States | Novum Investigator Site | Chandler | Arizona |
| United States | Novum Investigator Site | Charlotte | North Carolina |
| United States | Novum Investigator Site | Charlottesville | Virginia |
| United States | Novum Investigator Site | Chattanooga | Tennessee |
| United States | Novum Investigator Site | Cleveland | Ohio |
| United States | Novum Investigator Site | Columbus | Ohio |
| United States | Novum Investigator Site | Daytona Beach | Florida |
| United States | Novum Investigator Site | Denver | Colorado |
| United States | Novum Investigator Site | Duncansville | Pennsylvania |
| United States | Novum Investigator Site | Garden Grove | California |
| United States | Novum Investigator Site | Henderson | Nevada |
| United States | Novum Investigator Site | Hialeah | Florida |
| United States | Novum Investigator Site | Hickory | North Carolina |
| United States | Novum Investigator Site | High Point | North Carolina |
| United States | Novum Investigator Site | Hollywood | Maryland |
| United States | Novum Investigator Site | Houston | Texas |
| United States | Novum Investigator Site | Huntsville | Alabama |
| United States | Novum Investigator Site | Jupiter | Florida |
| United States | Novum Investigator Site | Lexington | Kentucky |
| United States | Novum Investigator Site | Little Rock | Arkansas |
| United States | Novum Investigator Site | Long Beach | California |
| United States | Novum Investigator Site | Longview | Texas |
| United States | Novum Investigator Site | Marietta | Georgia |
| United States | Novum Investigator Site | Mesa | Arizona |
| United States | Novum Investigator Site | Miami | Florida |
| United States | Novum Investigator Site | Midlothian | Virginia |
| United States | Novum Investigator Site | New Orleans1 | Louisiana |
| United States | Novum Investigator Site | Newport News | Virginia |
| United States | Novum Investigator Site | Norman | Oklahoma |
| United States | Novum Investigator Site | Norwalk | Connecticut |
| United States | Novum Investigator Site | Ormond Beach | Florida |
| United States | Novum Investigator Site | Phoenix | Arizona |
| United States | Novum Investigator Site | Pinellas Park | Florida |
| United States | Novum Investigator Site | Raleigh | North Carolina |
| United States | Novum Investigator Site | Sacramento | California |
| United States | Novum Investigator Site | Salisbury | North Carolina |
| United States | Novum Investigator Site | San Antonio | Texas |
| United States | Novum Investigator Site | San Diego | California |
| United States | Novum Investigator Site | Sandy Springs | Georgia |
| United States | Novum Investigator Site | Sarasota | Florida |
| United States | Novum Investigator Site | St. Petersburg | Florida |
| United States | Novum Investigator Site | Stamford | Connecticut |
| United States | Novum Investigator Site | Stock Bridge | California |
| United States | Novum Investigator Site | Sugar Land | Texas |
| United States | Novum Investigator Site | Tampa | Florida |
| United States | Novum Investigator Site | Tuscon | Arizona |
| United States | Novum Investigator Site | Wilmington | North Carolina |
| United States | Novum Investigator Site | Winston-Salem | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Anchen Pharmaceuticals, Inc | Novum Pharmaceutical Research Services |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Mean Change from Baseline in WOMAC Pain Scale | Baseline and Week 4 | No | |
| Secondary | Superiority of Test and Reference against Placebo in the Mean Change from baseline in the total WOMAC pain score. | The superiority of treatment over the placebo will be concluded if the treatment's mean change from baseline in the total WOMAC pain score is statistically significantly greater (p<0.05) than that of the placebo in the ANCOVA based on the treatment and placebo results. The superiority of Test and Reference treatments over the placebo will be evaluated identically in a separate ANCOVA. The analyses will be conducted in the mITT population. |
Baseline and Week 4 | No |